FGFR2 and non-small cell lung carcinoma: Based on the results from this study, it can be hypothesized that there was co-occurrence of clones with METex14 and non-genetic subclone with FGFR2 overexpression (FGFR-Activated subtype) or by WNT, ERBB2, MAPK pathways (Bypass-Activated subtype) in part of METex14 NSCLC.